Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of BG00012 (Dimethyl Fumarate) from Two Manufacturers
NCT02171208Phase 1Completed
- Sponsor
- Biogen
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dimethyl fumarate in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoints: Area under the concentration-time curve from time 0 to infinity up to 48 hours and Maximum observed concentration up to 48 hours. Started Jun 2014; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02171208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171208.